Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Psoriasis 1
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
01
Overview
"Psoriasis 1" is a Chinese herbal medicine (CHM) formulation widely utilized in China for the treatment of psoriasis. Its therapeutic efficacy stems from its ability to mitigate psoriasis-like skin inflammation by inhibiting the Vitamin D receptor (VDR)-mediated nuclear NF-κB and STAT signaling pathways. This action leads to a downregulation of pro-inflammatory cytokines such as TNF-α, IFN-γ, IL-22, IL-17C, IL-1β, and IL-4, while simultaneously upregulating 25-hydroxyvitamin D3 (25HVD3).
- Other names
- Chinese herbal medicine formulation 'Psoriasis 1'
02
Targets
AHR (Aryl hydrocarbon receptor)ROR (Retinoic acid receptor-related Orphan Receptor)VDR (Vitamin D receptor)CHUK (IKKα)NF-κBSTAT3 (Signal Transducer and Activator of Transcription 3)STAT4
Beyond the preview
Go deeper on Psoriasis 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Psoriasis 1.